CD8A and familial pancreatic carcinoma: These findings suggest that the antitumor activity of αMSLN is partially dependent on CD3+CD8+ T cells, highlighting its potential as a novel strategy to enhance the immunotherapeutic efficacy for pancreatic cancer patients.